Get the app!
Back to Trades
Other3

Kailera Therapeutics, Inc.

KLRA

Total Value
$NaN

Company Information

Ticker Symbol
KLRA
CIK
0002096997

Insider Information

Role
10% Owner
10% Owner

Filing Details

Filing Date
Apr 16, 2026
Transaction Date
Apr 16, 2026
Accession Number
0001104659-26-044508
Form Type
3

Footnotes

  1. (F1)The reported securities are directly held by Hengrui (USA) Ltd. Hengrui (USA) Ltd. is a wholly-owned subsidiary of Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  2. (F2)The Series A-2 convertible preferred stock and Series A-2 convertible non-voting preferred stock (collectively, the "Preferred Stock") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock will automatically convert into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

SEC Filing

View on SEC Daily

View the complete filing document on SEC Daily.